for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Celcuity Inc

CELC.OQ

Latest Trade

18.39USD

Change

0.00(0.00%)

Volume

96

Today's Range

18.27

 - 

18.27

52 Week Range

15.74

 - 

30.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
18.39
Open
18.27
Volume
96
3M AVG Volume
0.19
Today's High
18.27
Today's Low
18.27
52 Week High
30.00
52 Week Low
15.74
Shares Out (MIL)
10.24
Market Cap (MIL)
188.30
Forward P/E
-27.45
Dividend (Yield %)
--

Next Event

Q3 2019 Celcuity Inc Earnings Release

Latest Developments

More

Celcuity Reports Q2 Loss Per Share $0.17

Celcuity Reports Fourth Quarter And Full Year 2018 Financial Results

Celcuity Reports Third Quarter 2018 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Celcuity Inc

Celcuity, Inc. is a cellular analysis company. The Company is focused on discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The Company’s proprietary CELx diagnostic platform uses a patient’s living tumor cells to identify the specific abnormal cellular process driving a patient’s cancer and the targeted therapy that best treats it. CELx platform provides traditional molecular diagnostics, which provides a snapshot of the genetic mutations present in a patient’s tumor because they analyze dead cells. Using dead cells prevents molecular diagnostics from analyzing in real-time the dynamic cellular activities, known as cell signaling, that regulate cell proliferation or survival.

Industry

Biotechnology & Drugs

Contact Info

16305 36th Ave N Ste 100

+1.763.3920767

http://celcuity.com/

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2017

-0.660

2018

-0.620

2019(E)

-0.670
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
8.39
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.10
LT Debt To Equity (MRQ)
0.08
Return on Investment (TTM)
-28.44
Return on Equity (TTM)
-27.45

Latest News

BRIEF-Celcuity Q1 Loss Per Share $0.19

* CELCUITY-INTERIM RESULTS OF CLINICAL TRIAL IN COLLABORATION WITH NSABP FOUNDATION, GENENTECH EXPECTED IN Q1 OR Q2 2019, INSTEAD OF 2018 END ANTICIPATED EARLIER Source text for Eikon: Further company coverage:

BRIEF-Celcuity Reports Q4 Adjusted Non-Gaap Loss Per Share $0.14

* CELCUITY REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Celcuity reports Q3 loss $0.26/shr

* Celcuity reports third quarter fiscal 2017 financial results

BRIEF-Celcuity announces pricing of initial public offering

* Celcuity Llc - announced today pricing of its upsized IPO of 2,400,000 shares of its common stock at a public offering price of $9.50 per share

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up